US EditionPublished • loading... • Updated
Astrazeneca: Margins Do Not Meet Expectations
Summary by Merca2.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Citigroup analysts point out that the forecasts for the profit per share (BPA) for fiscal year 2025 and fiscal year 2026 in AstraZeneca are online. The margins for the fourth quarter do not meet expectations, but the forecasts for 2026, which point to 35%, reassure. Graham Parry, the analyst for Citi who carries the pharmaceutical sector explains that the profit per share (BPA) for fiscal year 2025, of 9.16 dollars, and the forecasts for the fis…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
